Stockscreener 앱 받기
1.09
2.36%
0.03
시간 외 거래:
1.09
전일 마감가:
$1.06
열려 있는:
$1.08
하루 거래량:
823.85K
Relative Volume:
1.98
시가총액:
$96.22M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.25%
1개월 성능:
-5.65%
6개월 성능:
-41.98%
1년 성능:
-0.46%
1일 변동 폭
$1.04
$1.10
1주일 범위
$1.01
$1.12
52주 변동 폭
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(908) 967-6677
주소
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.09 | 93.57M | 0 | 0 | 0 | 0.00 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-11-27 | 개시 | Maxim Group | Buy |
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology reports 86% response rate in lymphoma study - Investing.com India
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
CTOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Outlook: Can Citius Oncology Inc keep up with sector leadersJuly 2025 Highlights & High Accuracy Buy Signal Tips - baoquankhu1.vn
Aug Selloffs: What are Merus NVs earnings expectationsMarket Weekly Review & Smart Swing Trading Alerts - baoquankhu1.vn
Aug Drivers: Is TCRT stock showing strong momentumMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Is Citius Oncology Inc. stock a contrarian buyTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug PreEarnings: Can Citius Oncology Inc lead its sector in growth2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Armistice Capital reports 8.08M Citius Oncology (NASDAQ: CTOR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
CTOR PE Ratio & Valuation, Is CTOR Overvalued - Intellectia AI
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat
Earnings Breakdown: Citius Oncology Q1 - Benzinga
CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Press Release: Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM) - 富途牛牛
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Sahm
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius inks EU distribution agreement for CTCL treatment - The Pharma Letter
Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir - Bitget
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday - MarketBeat
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January - MarketBeat
Interleukin-2 (IL-2) Market to Grow Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eisai, Citius Oncology, Corvus Pharmaceuticals, ILTOO Pharma - Barchart.com
CEO Moves: Why is Citius Oncology Inc stock going down2025 Trading Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Decliners Report: Is Citius Oncology Inc undervalued by DCF analysisJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com
Dow Update: Why is Citius Oncology Inc stock going downWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2% - MarketBeat
Profit Review: Is Citius Oncology Inc likely to announce a buybackJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st
Can Citius Oncology Inc. stock beat market expectations this quarterJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
Does Citius Oncology Inc. stock trade at a discount to peersPrice Action & Daily Chart Pattern Signals - Улправда
How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - Улправда
Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда
Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Oncology raises $18M through direct offering - MSN
News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent
Citius Oncology Inc (CTOR) 재무 분석
Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.18%
1.85%
자본화:
|
볼륨(24시간):